Active Grant Support

National Institutes of Allergy and Infectious Disease, NIH
RO1 AI45642  "Mimetics of capsular epitopes of Neisseria meningitidis group B"
PI. Gregory Moe
Entire project period 4/1/2000 to 3/31/2005

National Institutes of Allergy and Infectious Disease, NIH
RO1 AI46464  "Novel vaccine approaches for N. meningitidis disease"
PI. Dan Granoff
Entire project period 12/1/99 to 1/31/2008

National Institutes of Allergy and Infectious Disease, NIH
RO1 AI058122  “Molecular basis of group A anticapsular immunity”
PI. Dan Granoff
Entire project period6/1/2004 to 5/31/2008

National Institutes of Allergy and Infectious Disease, NIH
R21 AI061533  “Neisseria meningitidis antigens expressed in infection”
PI. Dan Granoff
Entire project period6/1/2004 to 5/31/2006

National Institutes of Allergy and Infectious Disease, NIH
R43 AI58431  “Prevention of group B Neisseria meningitidis infection”
PI. Randall Mrsny
Entire project period7/1/2004 to 6/30/2005

Program for Appropriate Technology for Health (PATH)
GAT.0779-07014  “Development of a group A meningococcal infant rat bacteremia model”
PI. Dan Granoff
Entire project period2/9/2004 to 2/8/2005

Aventis Pasteur
"Development of proper laboratory testing procedures for meningococcal antibodies”
PI. Dan Granoff
Entire project period 10/1/2000 to 11/01/2005

Bioveris Corporation
“Polysaccharide derivatives and uses in induction of an immune response”
PI. Gregory Moe
Entire project period11/1/2004 to 10/31/2005

Patents

Granoff DM and Moe GR. Antibodies that define unique meningococcal B epitopes and vaccine compositions. U.S. patent 6,048,527.

Granoff DM and Moe GR. Molecular mimetics of meningococcal B epitopes. U.S. patent 6,030,619.

Granoff, DM. Methods of immunizing adults using anti-meningococcal vaccine compositions. U.S. patent 6,413,520.